Product image of Javlor (Vinflunine) supplied by GNH India

Javlor

Active Ingredient:
Vinflunine
Origin:
EU

Javlor (Vinflunine)

Vinflunine, the active ingredient in Javlor, is a Vinca alkaloid presented as a sterile solution for injection for intravenous use. It is indicated for the treatment of advanced or metastatic urothelial carcinoma in adult patients who have progressed after prior platinum‑based chemotherapy, offering an option when standard regimens have failed. The drug is marketed in the European Union and conforms to international quality standards.

GNH India supplies Javlor as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, specialty pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pierre Fabre Medicament

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Javlor (vinflunine) is used in the management of urothelial carcinoma, a cancer of the urinary tract.
  • Advanced urothelial carcinoma (bladder): provides a treatment option after failure of platinum‑based chemotherapy.
  • Advanced urothelial carcinoma (ureter): offers therapeutic benefit when disease progresses following standard regimens.
  • Advanced urothelial carcinoma (renal pelvis): used as a later‑line therapy for patients with refractory disease.

How It Works

  • Vinflunine binds to tubulin and inhibits microtubule dynamics, disrupting the mitotic spindle formation required for cell division. This interference leads to cell‑cycle arrest at the G2/M phase and triggers apoptotic pathways in rapidly proliferating cancer cells, thereby reducing tumor growth in urothelial carcinoma.

Side Effects

Vinflunine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Neutropenia: reduced white blood cell count increasing infection risk.
  • Anemia: lowered red blood cells causing fatigue.
  • Nausea and vomiting: gastrointestinal upset.
  • Constipation: decreased bowel movements.
  • Fatigue: general weakness and tiredness.
  • Alopecia: hair loss.

Serious or Rare Side Effects

  • Severe neutropenia with febrile infection.
  • Hemorrhage or bleeding complications.
  • Cardiac toxicity such as arrhythmias.
  • Acute renal failure.
  • Anaphylactic or severe allergic reactions.
  • Thromboembolic events.

Precautions & Warnings

  • Vinflunine requires careful monitoring and specific safety measures before and during therapy.
  • Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia.
  • Assess renal function: evaluate serum creatinine and glomerular filtration rate prior to each dose.
  • Check hepatic function: monitor liver enzymes for potential hepatotoxicity.
  • Avoid use in active severe infection: postpone treatment until infection is controlled.
  • Use caution in patients with cardiac disease: observe for signs of arrhythmia or ischemia.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vinflunine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

  • Concomitant Vinca alkaloids or other microtubule inhibitors: additive toxicity.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinflunine exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce vinflunine effectiveness.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): increased bleeding risk, monitor INR.
  • Nephrotoxic agents (e.g., cisplatin, aminoglycosides): heightened renal toxicity, check renal parameters.
  • Other myelosuppressive drugs (e.g., cyclophosphamide): enhanced bone‑marrow suppression, observe blood counts.

Frequently Asked Questions

Javlor contains the chemotherapeutic agent vinflunine and is indicated for the treatment of adult patients with advanced or metastatic urothelial carcinoma who have progressed after prior platinum‑based chemotherapy. It provides a later‑line option when standard regimens are no longer effective.

Vinflunine belongs to the Vinca alkaloid class and binds to tubulin, preventing the assembly and disassembly of microtubules. This disruption halts cell division at the G2/M phase and activates programmed cell death pathways, thereby reducing tumor cell proliferation in urothelial cancers.

The dose of Javlor is individualized by the prescribing oncologist based on factors such as patient weight, renal function, prior therapy, and tolerance. The prescriber determines the appropriate infusion schedule and any necessary dose adjustments.

Safety data for vinflunine in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To request Javlor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Javlor (vinflunine) is a microtubule‑targeting agent used after failure of platinum‑based regimens, whereas alternatives may include immunotherapy (e.g., pembrolizumab) or other chemotherapies such as taxanes. Vinflunine offers a distinct mechanism of action and may be chosen based on prior treatment history, toxicity profile and patient comorbidities.

Javlor should be stored refrigerated at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. Follow any additional handling instructions provided with the product.

Javlor is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The infusion is typically given over a specified period, with pre‑medication and monitoring as directed by the treating oncologist.

The most serious risks include severe neutropenia with febrile infection, hemorrhage, cardiac toxicity, acute renal failure, and rare but life‑threatening allergic reactions. Patients should be closely monitored for signs of infection, bleeding, cardiac events, and renal impairment throughout treatment.

Javlor is contraindicated in patients with known hypersensitivity to vinflunine or any component of the formulation, in those with uncontrolled severe infection, and in individuals with significant baseline cardiac, hepatic or renal dysfunction where the risk outweighs potential benefit. The prescribing physician must assess suitability on a case‑by‑case basis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Vinflunine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT